
Amneal Pharmaceuticals, Inc.
AMRXNASDAQHealthcareDrug Manufacturers - Specialty & Generic
Regular session
$17.692
−$0.088 · -0.49%
AMRX company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
61
Undervalued
Momentum
67
Gaining
Sentiment
64
Bullish
Risk resilience
66
Moderate Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteAmneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Chirag K. Patel
- Listed since
- May 7, 2018
- Employees
- 8,700
Market position
Day range
Current $17.692
52-week range
Current $17.692
- Open
- $17.78
- Previous close
- $17.78
- Volume
- 289.55K
- 0.15× average
- Average volume
- 1.89M
- Average daily volume
- Market cap
- 5.65B USD
- Beta
- 1.26
- Market reference 1
- 50-day average
- $17.5358
- +0.89% above average
- 200-day average
- $14.0959
- +25.51% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 6.37B USD
- P/E (TTM)
- 35.57×
- P/B (TTM)
- 171.03×
- P/S (TTM)
- 1.81×
- EV / EBITDA
- 10.56×
- Earnings yield
- 1.82%
- Free cash flow yield
- 6.84%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 39.32%
- Operating margin
- 12.93%
- Net margin
- 5.05%
- Return on equity
- -101.78%
- Return on assets
- 1.96%
- Return on invested capital
- 13.80%
Financial health
- Debt / equity
- 84.54×
- Current ratio
- 2.17×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 3.02B USD | 2.79B USD | 2.39B USD | 2.21B USD | 2.09B USD |
| Cost of goods sold | 1.88B USD | 1.77B USD | 1.53B USD | 1.42B USD | 1.32B USD |
| Gross profit | 1.14B USD | 1.02B USD | 863.87M USD | 791.46M USD | 768.97M USD |
| Research and development | 186.18M USD | 190.71M USD | 194.75M USD | 208.66M USD | 209.56M USD |
| Selling, general, and administrative | 526.83M USD | 476.44M USD | 429.68M USD | 399.7M USD | 365.5M USD |
| Operating expenses | 713M USD | 771.11M USD | 659.5M USD | 886.39M USD | 616.26M USD |
| Interest expense | 241.09M USD | 258.6M USD | 210.63M USD | 158.38M USD | 136.33M USD |
| Depreciation and amortization | 223.57M USD | 236.19M USD | 229.4M USD | 240.18M USD | 233.41M USD |
| Operating income | 423.09M USD | 249.33M USD | 204.37M USD | −94.93M USD | 152.72M USD |
| Net income | 72.06M USD | −116.89M USD | −83.99M USD | −129.99M USD | 10.62M USD |
Company facts updated Aug 25, 2026.
Earnings
- EPS beat rate
- 91%
- 10 beats, 1 miss, 0 met estimates
- Average EPS surprise
- +35.72%
- 11 comparable reports
- Latest EPS result
- 0.3
- Estimate 0.22 · Beat by 34.83%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Rating distribution
17 ratingsAMRX peers
ETFs holding AMRX
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Small-Cap ETFIJR192.89M0.17%110.76B USD0.06%$146.37-0.28%
Vanguard Morningstar Total Stock Market ETFVTI102.35M0.00%2.3T USD0.03%$377.98+0.24%
iShares Russell 2000 ETFIWM77.03M0.10%80.54B USD0.19%$298.69+0.24%
Vanguard Morningstar Small-Cap ETFVB73.92M0.04%183.4B USD0.03%$302.77-0.04%
Vanguard Morningstar Small-Cap Value ETFVBR46.93M0.07%68.3B USD0.05%$247.91-0.21%
Vanguard Extended Market ETFVXF36.32M0.04%93.7B USD0.05%$243.62+0.08%
Invesco S&P SmallCap Momentum ETFXSMO33.19M1.10%3.04B USD0.36%$85.215-0.06%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM28.91M0.17%17.14B USD0.03%$56.915-0.25%
iShares Core S&P Small-Cap ETFIJR- Market value
- 192.89M
- Weight
- 0.17%
- AUM
- 110.76B USD
- Expense ratio
- 0.06%
- Price / 1D
- $146.37-0.28%
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 102.35M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $377.98+0.24%
iShares Russell 2000 ETFIWM- Market value
- 77.03M
- Weight
- 0.10%
- AUM
- 80.54B USD
- Expense ratio
- 0.19%
- Price / 1D
- $298.69+0.24%
Vanguard Morningstar Small-Cap ETFVB- Market value
- 73.92M
- Weight
- 0.04%
- AUM
- 183.4B USD
- Expense ratio
- 0.03%
- Price / 1D
- $302.77-0.04%
Vanguard Morningstar Small-Cap Value ETFVBR- Market value
- 46.93M
- Weight
- 0.07%
- AUM
- 68.3B USD
- Expense ratio
- 0.05%
- Price / 1D
- $247.91-0.21%
Vanguard Extended Market ETFVXF- Market value
- 36.32M
- Weight
- 0.04%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $243.62+0.08%
Invesco S&P SmallCap Momentum ETFXSMO- Market value
- 33.19M
- Weight
- 1.10%
- AUM
- 3.04B USD
- Expense ratio
- 0.36%
- Price / 1D
- $85.215-0.06%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM- Market value
- 28.91M
- Weight
- 0.17%
- AUM
- 17.14B USD
- Expense ratio
- 0.03%
- Price / 1D
- $56.915-0.25%
Continue in GoAI
Research AMRXresearch.disclaimer





